Related StoriesNovo Nordisk announces FDA acceptance of Tresiba for diabetes treatmentInsulin dosage not independent risk factor for cardiovascular deathHigher insulin levels linked to even worse prognosis in advanced breasts cancer We are worked up about this collaboration with bioRASI and the technique we set forth in this contract, said Jeffrey Davis, Access Pharmaceuticals’ President and CEO. bioRASI is usually a full-service global CRO specializing in the accelerated development of novel therapeutics through its close collaboration with the Russian Academy of Sciences and extensive knowledge with Russian and additional Eastern European regulatory systems.Richard A. Miech, Ph.D., M.P.H., of Johns Hopkins University, Baltimore, and colleagues examined styles in the prevalence of overweight among adolescents aged 12 to 17 years by family poverty status. The researchers utilized data from four cross-sectional, nationally representative surveys . The authors found that styles in the association of adolescent overweight with family poverty differed by age ranges. There is a widening disparity among 15 – to 17-year-aged adolescents from poor households. This trend was related among male, female, non-Hispanic white, and non-Hispanic black adolescents, leading to a standard prevalence of over weight in 1999-2004 more than 50 % higher among adolescents in poor vs.